By providing a scalable, versatile solution for amplifying virus- and cancer-specific CD8+ T cells, αCD28-IST has the potential to revolutionize immunotherapy, paving the way for innovative treatments for HIV, other persistent infections, and cancer. Here, CD8A is linked to cancer.